Literature DB >> 31112989

Reduced safety processing during aversive social conditioning in psychosis and clinical risk.

Megan Quarmley1, Ruben C Gur1, Bruce I Turetsky1, Anna J Watters1, Warren B Bilker2, Mark A Elliott3, Monica E Calkins1, Christian G Kohler1, Kosha Ruparel1, Petra Rupert1, Raquel E Gur1, Daniel H Wolf4.   

Abstract

Social impairment occurs across the psychosis spectrum, but its pathophysiology remains poorly understood. Here we tested the hypothesis that reduced differential responses (aversive vs. neutral) in neural circuitry underpinning aversive conditioning of social stimuli characterizes the psychosis spectrum. Participants age 10-30 included a healthy control group (HC, analyzed n = 36) and a psychosis spectrum group (PSY, n = 71), including 49 at clinical risk for psychosis and 22 with a frank psychotic disorder. 3T fMRI utilized a passive aversive conditioning paradigm, with neutral faces as conditioned stimuli (CS) and a scream as the unconditioned stimulus. fMRI conditioning was indexed as the activation difference between aversive and neutral trials. Analysis focused on amygdala, ventromedial prefrontal cortex, and anterior insula, regions previously implicated in aversive and social-emotional processing. Ventromedial prefrontal cortex activated more to neutral than aversive CS; this "safety effect" was driven by HC and reduced in PSY, and correlated with subjective emotional ratings following conditioning. Insula showed the expected aversive conditioning effect, and although no group differences were found, its activation in PSY correlated with anxiety severity. Unexpectedly, amygdala did not show aversive conditioning; its activation trended greater for neutral than aversive CS, and did not differ significantly based on group or symptom severity. We conclude that abnormalities in social aversive conditioning are present across the psychosis spectrum including clinical risk, linked to a failure of safety processing. Aversive and safety learning provide translational paradigms yielding insight into pathophysiology of psychosis risk, and providing potential targets for therapeutic and preventative interventions.

Entities:  

Mesh:

Year:  2019        PMID: 31112989      PMCID: PMC6898578          DOI: 10.1038/s41386-019-0421-9

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  48 in total

1.  Amygdala recruitment in schizophrenia in response to aversive emotional material: a meta-analysis of neuroimaging studies.

Authors:  Alan Anticevic; Jared X Van Snellenberg; Rachel E Cohen; Grega Repovs; Erin C Dowd; Deanna M Barch
Journal:  Schizophr Bull       Date:  2010-12-01       Impact factor: 9.306

2.  Toward Improved Risk Prediction in Individuals at High Risk of Psychotic Disorders.

Authors:  Alison R Yung
Journal:  Am J Psychiatry       Date:  2015-10       Impact factor: 18.112

3.  Prevalence of item level negative symptoms in first episode psychosis diagnoses.

Authors:  John Lyne; Brian O'Donoghue; Elizabeth Owens; Laoise Renwick; Kevin Madigan; Anthony Kinsella; Mary Clarke; Niall Turner; Eadbhard O'Callaghan
Journal:  Schizophr Res       Date:  2012-01-27       Impact factor: 4.939

4.  The NIMH-MATRICS consensus statement on negative symptoms.

Authors:  Brian Kirkpatrick; Wayne S Fenton; William T Carpenter; Stephen R Marder
Journal:  Schizophr Bull       Date:  2006-02-15       Impact factor: 9.306

5.  The current conceptualization of negative symptoms in schizophrenia.

Authors:  Stephen R Marder; Silvana Galderisi
Journal:  World Psychiatry       Date:  2017-02       Impact factor: 49.548

Review 6.  Social cognition in schizophrenia.

Authors:  Michael F Green; William P Horan; Junghee Lee
Journal:  Nat Rev Neurosci       Date:  2015-09-16       Impact factor: 34.870

7.  Social functioning in young people at risk for schizophrenia.

Authors:  Jacob S Ballon; Tejal Kaur; Iliana I Marks; Kristin S Cadenhead
Journal:  Psychiatry Res       Date:  2007-03-26       Impact factor: 3.222

8.  Social disability in schizophrenic, schizoaffective and affective disorders 15 years after first admission.

Authors:  Ronald Bottlender; Anton Strauss; Hans-Jürgen Möller
Journal:  Schizophr Res       Date:  2010-01       Impact factor: 4.939

9.  Limbic activation associated with misidentification of fearful faces and flat affect in schizophrenia.

Authors:  Raquel E Gur; James Loughead; Christian G Kohler; Mark A Elliott; Kathleen Lesko; Kosha Ruparel; Daniel H Wolf; Warren B Bilker; Ruben C Gur
Journal:  Arch Gen Psychiatry       Date:  2007-12

10.  PARANOID INDIVIDUALS WITH SCHIZOPHRENIA SHOW GREATER SOCIAL COGNITIVE BIAS AND WORSE SOCIAL FUNCTIONING THAN NON-PARANOID INDIVIDUALS WITH SCHIZOPHRENIA.

Authors:  Amy E Pinkham; Philip D Harvey; David L Penn
Journal:  Schizophr Res Cogn       Date:  2016-01-13
View more
  4 in total

1.  Linking Salience Signaling With Early Adversity and Affective Distress in Individuals at Clinical High Risk for Psychosis: Results From an Event-Related fMRI Study.

Authors:  Zachary B Millman; Jason Schiffman; James M Gold; LeeAnn Akouri-Shan; Caroline Demro; John Fitzgerald; Pamela J Rakhshan Rouhakhtar; Mallory Klaunig; Laura M Rowland; James A Waltz
Journal:  Schizophr Bull Open       Date:  2022-06-17

2.  Impairment in acquisition of conditioned fear in schizophrenia.

Authors:  Lauri Tuominen; Liana Romaniuk; Mohammed R Milad; Donald C Goff; Jeremy Hall; Daphne J Holt
Journal:  Neuropsychopharmacology       Date:  2021-09-29       Impact factor: 7.853

3.  BDNF haploinsufficiency induces behavioral endophenotypes of schizophrenia in male mice that are rescued by enriched environment.

Authors:  Mahmoud Harb; Justina Jagusch; Archana Durairaja; Thomas Endres; Volkmar Leßmann; Markus Fendt
Journal:  Transl Psychiatry       Date:  2021-04-22       Impact factor: 6.222

Review 4.  Neural correlates of emotional processing in psychosis risk and onset - A systematic review and meta-analysis of fMRI studies.

Authors:  P B Lukow; A Kiemes; M J Kempton; F E Turkheimer; P McGuire; G Modinos
Journal:  Neurosci Biobehav Rev       Date:  2021-03-17       Impact factor: 8.989

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.